Innate Pharma (IPHA) Net Income (2019 - 2025)
Historic Net Income for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to -$25.6 million.
- Innate Pharma's Net Income rose 193.0% to -$25.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$106.5 million, marking a year-over-year decrease of 23635.95%. This contributed to the annual value of -$133652.4 for FY2022, which is 9840.63% up from last year.
- Innate Pharma's Net Income amounted to -$25.6 million in Q2 2025, which was up 193.0% from -$48.6 million recorded in Q4 2024.
- Innate Pharma's Net Income's 5-year high stood at $7.5 million during Q2 2021, with a 5-year trough of -$48.6 million in Q4 2024.
- Over the past 5 years, Innate Pharma's median Net Income value was -$6.2 million (recorded in 2023), while the average stood at -$11.9 million.
- The largest annual percentage gain for Innate Pharma's Net Income in the last 5 years was 89402.78% (2023), contrasted with its biggest fall of 461673871.47% (2023).
- Innate Pharma's Net Income (Quarter) stood at -$8.4 million in 2021, then soared by 100.0% to -$133.65 in 2022, then tumbled by 4616738.71% to -$6.2 million in 2023, then tumbled by 687.89% to -$48.6 million in 2024, then soared by 47.32% to -$25.6 million in 2025.
- Its last three reported values are -$25.6 million in Q2 2025, -$48.6 million for Q4 2024, and -$26.1 million during Q2 2024.